Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CRSP 
Crispr Therapeutics AG (CRSP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/30/2025: CRSP (1-star) is a SELL. SELL since 2 days. Simulated Profits (0.39%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
28 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $82.95
1 Year Target Price $82.95
| 12 | Strong Buy |
| 5 | Buy |
| 10 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 16.52% | Avg. Invested days 24 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/30/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.69B USD | Price to earnings Ratio - | 1Y Target Price 82.95 |
Price to earnings Ratio - | 1Y Target Price 82.95 | ||
Volume (30-day avg) 28 | Beta 1.83 | 52 Weeks Range 30.04 - 78.48 | Updated Date 10/30/2025 |
52 Weeks Range 30.04 - 78.48 | Updated Date 10/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.4 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-05 | When After Market | Estimate -1.31 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -14918.27% |
Management Effectiveness
Return on Assets (TTM) -13.05% | Return on Equity (TTM) -25.34% |
Valuation
Trailing PE - | Forward PE 23.36 | Enterprise Value 5117224802 | Price to Sales(TTM) 149.54 |
Enterprise Value 5117224802 | Price to Sales(TTM) 149.54 | ||
Enterprise Value to Revenue 146.21 | Enterprise Value to EBITDA 14.16 | Shares Outstanding 90950423 | Shares Floating 90452015 |
Shares Outstanding 90950423 | Shares Floating 90452015 | ||
Percent Insiders 1.69 | Percent Institutions 80.76 |
Upturn AI SWOT
Crispr Therapeutics AG
Company Overview
History and Background
CRISPR Therapeutics was founded in 2013 by Emmanuelle Charpentier, Rodger Novak, Shaun Foy, and others, based on the CRISPR-Cas9 gene editing technology. The company has focused on developing gene-based medicines for serious diseases.
Core Business Areas
- Gene Editing Therapies: CRISPR Therapeutics focuses on developing therapies based on the CRISPR-Cas9 gene editing technology. This includes modifying, repairing, or deleting genes to treat or cure diseases.
- Hematology: Developing gene-edited cell therapies for blood disorders like sickle cell disease and beta thalassemia.
- Oncology: Developing allogeneic cell therapies targeting various cancers.
- Regenerative Medicine: Exploring gene editing to develop therapies for diseases like type 1 diabetes.
Leadership and Structure
The CEO is Samarth Kulkarni, PhD. The company has a standard organizational structure for a biotech firm, with departments dedicated to research, development, clinical trials, and commercialization.
Top Products and Market Share
Key Offerings
- Exagamglogene autotemcel (exa-cel, formerly CTX001): A gene-edited cell therapy developed in collaboration with Vertex Pharmaceuticals (VRTX) for sickle cell disease and beta thalassemia. While revenue data is still emerging post-approval, exa-cel represents the company's most advanced product. Competitors include conventional treatments like blood transfusions and bone marrow transplants, and gene therapies from companies like bluebird bio (BLUE).
- CTX110: An allogeneic CAR-T cell therapy targeting CD19+ malignancies. Currently in clinical trials. Competitors include approved CAR-T therapies from companies like Gilead (GILD) and Novartis (NVS).
Market Dynamics
Industry Overview
The gene editing industry is rapidly growing, with CRISPR technology at the forefront. It involves developing therapies that modify genes to treat or cure diseases. The market is competitive with both large pharmaceutical companies and smaller biotech firms.
Positioning
CRISPR Therapeutics is a leading company in the CRISPR-based gene editing field. Its competitive advantages include its pioneering role, established partnerships (e.g., with Vertex), and a diverse pipeline of therapeutic candidates.
Total Addressable Market (TAM)
The TAM for gene editing therapies is estimated to reach billions of dollars in the coming years. CRISPR Therapeutics is well-positioned to capture a significant share of this market, particularly in areas like hematology and oncology.
Upturn SWOT Analysis
Strengths
- Pioneering CRISPR technology platform
- Strategic partnership with Vertex Pharmaceuticals
- Strong intellectual property position
- Advanced clinical pipeline
- Experienced management team
Weaknesses
- High research and development costs
- Regulatory hurdles for gene editing therapies
- Competition from other gene editing companies
- Dependence on successful clinical trial outcomes
- Manufacturing complexities
Opportunities
- Expanding therapeutic applications of CRISPR technology
- Entering new disease areas
- Strategic collaborations and acquisitions
- Growing demand for gene editing therapies
- Potential for curative treatments
Threats
- Adverse clinical trial results
- Regulatory setbacks
- Patent disputes
- Ethical concerns surrounding gene editing
- Competition from alternative therapies
Competitors and Market Share
Key Competitors
- EDIT
- BLUE
- BEAM
Competitive Landscape
CRISPR Therapeutics has a first-mover advantage but faces increasing competition. EDITAS Medicine (EDIT) and Beam Therapeutics (BEAM) are two well-known players. BLUEBIRD BIO (BLUE) used to be a leader but has seen considerable setbacks.
Major Acquisitions
TxCell
- Year: 2018
- Acquisition Price (USD millions): 76
- Strategic Rationale: Expanded CRISPR Therapeutics' capabilities in cell therapy manufacturing and development.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by research progress and partnership deals. The company's value has increased significantly based on the potential of its CRISPR platform.
Future Projections: Future growth is dependent on the successful commercialization of its lead product, exa-cel, and continued progress in its clinical pipeline. Analyst estimates suggest significant revenue growth in the coming years if exa-cel is successful.
Recent Initiatives: Recent initiatives include expanding clinical trials for exa-cel, advancing its oncology pipeline (CTX110, CTX130, etc.), and exploring new gene editing applications.
Summary
CRISPR Therapeutics is a prominent gene editing company with a strong foundation in CRISPR-Cas9 technology, highlighted by their partnership with Vertex and the recent FDA approval of exa-cel. While the company is still years away from profitability and heavily reliant on external funding and collaboration revenue, its pioneering position and pipeline of therapies offer considerable promise. Challenges remain in navigating regulatory hurdles and managing competition, and adverse outcomes in clinical trials remain a significant risk. The approval of exa-cel represents a critical de-risking milestone.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Filings (SEC), Investor Presentations, Analyst Reports, Industry News
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share estimates are approximate and may vary based on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Crispr Therapeutics AG
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2016-10-19 | CEO & Chairman Dr. Samarth Kulkarni Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 393 | Website https://www.crisprtx.com |
Full time employees 393 | Website https://www.crisprtx.com | ||
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting glypican-3 (GPC3) for the potential treatment of solid tumors. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.